Effects of disulfiram on proliferation, apoptosis and gefitinib resistance of lung cancer cell line H1975

doi:10.16352/j.issn.1001-6325.2026.10.1352

Abstract

Abstract: Objective To investigate the effects of disulfiram (DSF) on the proliferation, apoptosis and gefitinib sensitivity of non-small cell lung cancer H1975 cells. Methods H1975 cells were cultured in vitro and treated with different concentrations of disulfiram for 24, 48, and 72 hours. The CCK-8 assay was used to assess the impact of disulfiram on cell proliferation, and appropriate concentrations were selected for subsequent experiments. Cells were treated with varying concentrations of gefitinib alone or in combination with disulfiram for 48 hours, and the half-maximal inhibitory concentration (IC₅₀) was calculated to determine the reversal fold. Cells were treated with gefitinib, disulfiram and N-acetylcysteine alone or in combination for 48 hours. Apoptosis was detected by flow cytometry, intracellular reactive oxygen species levels were measured using the DCFH-DA method, and Western blotting was performed to assess the expression of stemness-related markers (ALDH1A1, SOX2), pathway-related markers (p-STAT3, STAT3), and apoptosis-related markers (Bax, Bcl-2). Results Disulfiram significantly inhibited H1975 cell proliferation in a concentration-dependent (0-10 μmol/L) and time-dependent (24-72 hours) manner (P＜0.05). The IC₅₀ of gefitinib alone was 11.13 μmol/L, which decreased to 4.148 μmol/L when combined with 1 μmol/L disulfiram, indicating that disulfiram effectively reversed gefitinib resistance by 2.68 times. Disulfiram significantly suppressed the upregulation of stem cell-related proteins SOX2 and ALDH1A1 induced by gefitinib (P＜0.05), and this effect was partially counteracted by the reactive oxygen species inhibitor N-acetylcysteine. Compared to gefitinib and disulfiram monotherapy groups, the combination therapy group exhibited significantly increased apoptosis rates, elevated reactive oxygen species levels and pro-apoptotic Bax expression, and reduced p-STAT3 and anti-apoptotic Bcl-2 expression (P＜0.05). Further clearance of reactive oxygen species with N-acetylcysteine reversed disulfiram′s inhibitory effect on the STAT3 pathway(P＜0.05). Conclusions Disulfiram may enhance gefitinib sensitivity by upregulating reactive oxygen species levels and inhibiting the STAT3 signaling pathway.

Key words: non-small-cell lung cancer, gefitinib resistance, disulfiram, ROS/STAT3 pathway

CLC Number:

R734.2

YIN Jie, WANG Xue, DENG Shukai. Effects of disulfiram on proliferation, apoptosis and gefitinib resistance of lung cancer cell line H1975[J]. Basic & Clinical Medicine, 2026, 46(10): 1352-1358.

References

[1] Hendriks LEL, Remon J, Faivre-Finn C, et al. Non-small-cell lung cancer[J]. Nat Rev Dis Primers, 2024, 10: 71.doi:10.1038/s41572-024-00551-9.
[2] Zhou F, Guo H, Xia Y, et al. The changing treatment landscape of EGFR-mutant non-small-cell lung cancer[J]. Nat Rev Clin Oncol, 2025, 22: 95-116.
[3] Xiao Z, Ding L, Yu Y, et al. Tanreqing injection inhibits stemness and enhances sensitivity of non-small cell lung cancer models to gefitinib through ROS/STAT3 signaling pathway[J]. J Cancer, 2024, 15: 4259-4274.
[4] Zha J, Chen F, Dong H, et al. Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition[J]. J Transl Med, 2014, 12: 163.doi:10.1186/1479-5876-12-163.
[5] Kim YJ, Kim JY, Lee N, et al. Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells[J]. Biochem Biophys Res Commun, 2017, 486: 1069-1076.
[6] Kona FR, Buac D, M Burger A. Disulfiram, and disulfiram derivatives as novel potential anticancer drugs targeting the ubiquitin-proteasome system in both preclinical and clinical studies[J]. Curr Cancer Drug Targets, 2011, 11: 338-346.
[7] Jin N, Zhu X, Cheng F, et al. Disulfiram/copper targets stem cell-like ALDH⁺ population of multiple myeloma by inhibition of ALDH1A1 and Hedgehog pathway[J]. J Cell Biochem, 2018, 119: 6882-6893.
[8] Yang Z, Guo F, Albers AE, et al. Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines[J]. Biomed Pharmacother, 2019, 113: 108727.doi:10.1016/j.biopha.2019.108727.
[9] Zhang S, Xiong X, Sun Y. Functional characterization of SOX2 as an anticancer target[J]. Signal Transduct Target Ther, 2020, 5: 135.doi:10.1038/s41392-020-0110-5.
[10] Zhou Y, Wang Y, Ju X, et al. Clinicopathological significance of ALDH1A1 in lung, colorectal, and breast cancers: a meta-analysis[J]. Biomark Med, 2015, 9: 777-790.
[11] Yao W, Wang L, Huang H, et al. All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells[J]. BMC Cancer, 2020, 20: 315.doi:10.1186/s12885-020-06818-0.
[12] Zhang J, Wang X, Vikash V, et al. ROS and ROS-mediated cellular signaling[J]. Oxid Med Cell Longev, 2016, 2016: 4350965.doi:10.1155/2016/4350965.
[13] 田宗源,李展,刘瑞霞. TERT调控线粒体氧化应激在疾病中的作用[J]. 基础医学与临床, 2024, 44: 1436-1441.
[14] Chen YJ, Wu JY, Deng YY, et al. Ginsenoside Rg3 in combination with artesunate overcomes sorafenib resistance in hepatoma cell and mouse models[J]. J Ginseng Res, 2022, 46: 418-425.
[15] Khan M, Maryam A, Saleem MZ, et al. Brevilin A induces ROS-dependent apoptosis and suppresses STAT3 activation by direct binding in human lung cancer cells[J]. J Cancer, 2020, 11: 3725-3735.